ESG Intelligence – Pharmaceuticals – 1st August to 24th November 2020

In the second of our monthly ESG sector profiles, we see the Pharma industry enter positive territory with an average score of +10. Four out of nine material issue areas score negatively in Q3. Negative materiality is mainly driven by Affordability & Pricing (-22%), Business Ethics (-7%) and Safety of Clinical Trial Participants (-6%).

Download the full report here.